Sudden infant death syndrome and secretin treatment for autism

Current Opinion in Pediatrics

Volumn 12, Issue 2, 2000, Pages 179-183

  Blatt, Steven D ^a   Meguid, Victoria ^a   Church, Catharine C ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SECRETIN;

AUTISM; DRUG EFFICACY; ENVIRONMENTAL FACTOR; HUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RISK FACTOR; SUDDEN INFANT DEATH SYNDROME;

AUTISTIC DISORDER; HUMANS; INFANT; LONG QT SYNDROME; SECRETIN; SUDDEN INFANT DEATH; SUPINE POSITION; TREATMENT OUTCOME;

EID: 0034104929     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200004000-00017     Document Type: Review

References (14)

1. 1 Centers for Disease Control: Assessment of infant sleeping position-selected states, 1996. JAMA 1998, 280:1899-1900.
2. 2 Li DK, Wi S: Maternal placental abnormality and the risk of Sudden Infant Death Syndrome. Am J Epidemiol 1999, 149:608-611. Impaired fetal development caused by placental abnormality may predispose infants fo a high risk of SIDS.
3. 3 Ueda Y, Stick SM, Hall G, Sly PD: Control of breathing in infants born to smoking mothers. J Pediatr 1999, 135:226-232. Does prenatal smoke exposure change the infant's ventilatory response to hypoxia? This study showed a reduced drive to breathe and blunted ventilatory response in infants of smoking mothers compared to those of nonsmoking mothers.
4. 4 Dwyer T, Ponsonby AL, Couper D: Tobacco smoke exposure at one month of age and subsequent risk of SIDS-a prospective study. Am J Epidemiol 1999, 149:593-602. The three-fold effect of maternal smoking on SIDS risk persists even after adjustment for birth weight, seasonality and sleep position. Paternal smoking did not have an independent effect on SIDS rate; prenatal and postnatal maternal smoking was significantly correlated with SIDS rate.
5. 5 Ottolini MC, Davis BE, Patel K, Sachs HC, Gershon NB, Moon RY: Prone infant sleeping despite the "Back to Sleep" campaign. Arch Pediatr Adolesc Med 1999, 153:512-517. This prospective study in the Washington, DC area followed more than 400 newborns prospectively. Frequent monitoring during the first six months of life was used to document the infant sleep position over time. Although only 11% slept prone at one week of age, by six months of age, 32% were sleeping prone. The parents also reported their reasons for changing sleep positions; two thirds of parents cited infant comfort.
6. 6 Davis BE, Moon RY, Sachs HC, Ottolini MC: Effects of sleep position on infant motor development. Pediatrics 1998, 102:1135-1140. This prospective study in the Washington, DC area followed more than 400 newborns prospectively. Infants who slept in the prone position attained some motor milestones sooner than infants who slept in the supine position. Although statistically significant, these results probably have limited clinical significance.
7. 7 Lucey JF: Comments on a Sudden Infant Death article in another journal. Pediatrics 1999, 103:812.
8. 8 Malloy MH, Freeman DH: Sudden Infant Death Syndrome among twins. Arch Pediatr Adolesc Med 1999, 153:736-740.
9. 9 Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabor L, Tildon J: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998, 9:9-15. This is the original paper reporting serendipitous findings with the use of secretin in the treatment of autism.
10. 10 Sandier A, Button K, DeWeese J, Girardi MA, Sheppard V, Bodfish JW: A double-blind, placebo-controlled study of synthetic human secretin in the treatment of autism and pervasive developmental disorder [abstract]. J Dev Behav Ped 20:400.
11. 11 Sandler A, Sutton K, DeWeese J, Girardi MA, Sheppard V, Bodfish JW: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorders. N Engl J Med 1999, 341:1801-1806. The first published clinical trial of secretin for the treatment of autism, this double-blind, placebo-controlled trial of secretin examined the efficacy of secretin in treating 20 children with autism. Using detailed developmental-psychological assessments and parental reports, no significant benefits of secretin were found.
12. 12 Chez M, Hammer M, Bagan B, Buchanan C, McCarthy K, Ovrutskaya I, et al.: Secretin used in the treatment of autism: a double-blind clinical trial in children. Ann Neural 1999, 46:523.
13. 13 Owley T, Steele E, Corsello C, Risi S, McKaig K, Lord C, et al.: A doubleblind placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape Gen Med 1999 [online]. Available at: http://medscape.-com/medscape/generalmedicine/journal/1999. Assessed October 6, 1999.
14. 14 Rimland B: Autism Research Institute [online]. Available at: http://www.-autism.com/ari.